ConductScience.org, home

Paper31364692

Seventy Years of Tuberculosis Prevention: Efficacy, Effectiveness, Toxicity, Durability, and Duration.

Salazar-Austin N and 3 others. Am J Epidemiol, 2019. Cited by 26 papers, by iCite.

Cite this record

ConductScience Library. Seventy Years of Tuberculosis Prevention: Efficacy, Effectiveness, Toxicity, Durability, and Duration. Papers, record 31364692. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31364692

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Seventy Years of Tuberculosis Prevention: Efficacy, Effectiveness, Toxicity, Durability, and Duration.
PubMed
Journal
Am J Epidemiol
PubMed
Year
2019
PubMed
Publication types
Historical Article, Journal Article, Research Support, N.I.H., Extramural, Review
PubMed
Citations, by iCite
26
iCite
Relative citation ratio, by iCite
1.32
iCite
Revised in PubMed
2020-12-31
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Salazar-Austin NNicole
2Dowdy DWDavid W
3Chaisson RERichard E
4Golub JEJonathan E

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
EpidemiologyMajor topic
TuberculosisMajor topic
HIV Infections
History, 20th Century
History, 21st Century
Humans

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
K23 HD096973NICHD NIH HHSUnited StatesK23HD096973PubMed and NIHNIH RePORTER
P30 AI094189NIAID NIH HHSUnited StatesP30AI094189PubMed and NIHNIH RePORTER

Download CSV of grants

References76

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
26366257Thirty years after isoniazid. Its impact on tuberculosis in children and adolescents.JAMA1984https://conductscience.org/library/papers/6366257PubMed
39519950Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection.Lancet1998https://conductscience.org/library/papers/9519950PubMed
49295239A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration.N Engl J Med1997https://conductscience.org/library/papers/9295239PubMed
510524579How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?Int J Tuberc Lung Dis1999https://conductscience.org/library/papers/10524579PubMed
612588714American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis.Am J Respir Crit Care Med2003https://conductscience.org/library/papers/12588714PubMed
721732833New regimens to prevent tuberculosis in adults with HIV infection.N Engl J Med2011https://conductscience.org/library/papers/21732833PubMed
825365974Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study.Clin Infect Dis2015https://conductscience.org/library/papers/25365974PubMed
929972628Maternal priorities for preventive therapy among HIV-positive pregnant women before and after delivery in South Africa: a best-worst scaling survey.J Int AIDS Soc2018https://conductscience.org/library/papers/29972628PubMed
1015831840Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis.Am J Respir Crit Care Med2005https://conductscience.org/library/papers/15831840PubMed
1121849286Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening.J Infect Dis2011https://conductscience.org/library/papers/21849286PubMed
1227522233The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis.Lancet Infect Dis2016https://conductscience.org/library/papers/27522233PubMed
1318989223Long-term effectiveness of diagnosing and treating latent tuberculosis infection in a cohort of HIV-infected and at-risk injection drug users.J Acquir Immune Defic Syndr2008https://conductscience.org/library/papers/18989223PubMed
1417589190The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil.AIDS2007https://conductscience.org/library/papers/17589190PubMed
1510732934
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.
JAMA2000https://conductscience.org/library/papers/10732934PubMed
1627780211The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling.PLoS Med2016https://conductscience.org/library/papers/27780211PubMed
1711330495Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.MMWR Morb Mortal Wkly Rep2001https://conductscience.org/library/papers/11330495PubMed
186754120Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis.Bull World Health Organ1982https://conductscience.org/library/papers/6754120PubMed
1929562983Predictors of isoniazid preventive therapy completion among adults newly diagnosed with HIV in rural Malawi.Int J Tuberc Lung Dis2018https://conductscience.org/library/papers/29562983PubMed
2028763500Child contact management in high tuberculosis burden countries: A mixed-methods systematic review.PLoS One2017https://conductscience.org/library/papers/28763500PubMed
211731596
A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council.
Am Rev Respir Dis1992https://conductscience.org/library/papers/1731596PubMed

See all 76 referencesDownload CSV of references

Cited by18

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 26 citations.

PMIDTitleJournalYearIn PapersSource
42182841Performance of TB Antigen-Based Skin Tests Amongst Healthcare Workers-Sevagram, India, 2023-2024.Open Forum Infect Dis2026https://conductscience.org/library/papers/42182841PubMed
42110218Analytic Considerations for the Evaluation of Tuberculosis Preventative Therapy Effectiveness Among People Living with HIV.Obs Stud2025https://conductscience.org/library/papers/42110218PubMed
41798867Non-adherence and its predictors among pediatric household contacts on tuberculosis preventive therapy in the 3HP era: A multicenter observational study.Ther Adv Infect Dis2026https://conductscience.org/library/papers/41798867PubMed
41711404Breakthrough Tuberculosis in a Large Cohort of People Living With HIV on Preventive Treatment.Trop Med Int Health2026https://conductscience.org/library/papers/41711404PubMed
41172413Treatment completion and challenges in rolling out 12-dose weekly rifapentine plus isoniazid to prevent tuberculosis among people living with HIV and pediatric household contacts in Brazil.J Bras Pneumol2025https://conductscience.org/library/papers/41172413PubMed
40986702The effectiveness of isoniazid preventive treatment among contacts of multidrug-resistant tuberculosis: a systematic review and individual-participant meta-analysis.Am J Respir Crit Care Med2026https://conductscience.org/library/papers/40986702PubMed
40349709
Simultaneous initiation of dolutegravir-based antiretroviral therapy and once-weekly rifapentine and isoniazid for tuberculosis prevention in antiretroviral-naive people with HIV: an open-label, non-randomised, phase 1/2 trial.
Lancet HIV2025https://conductscience.org/library/papers/40349709PubMed
40092514Investigating low uptake of tuberculin skin testing when integrated with active case-finding for TB.IJTLD Open2025https://conductscience.org/library/papers/40092514PubMed
39131593Rethinking latent TB? Think again.IJTLD Open2024https://conductscience.org/library/papers/39131593PubMed
38734022
Effectiveness of preventive treatment among different age groups and Mycobacterium tuberculosis infection status: a systematic review and individual-participant data meta-analysis of contact tracing studies.
Lancet Respir Med2024https://conductscience.org/library/papers/38734022PubMed
38076017A case of oral tuberculous ulcer and literature review.Clin Case Rep2023https://conductscience.org/library/papers/38076017PubMed
37879092US Guidelines Fall Short on Short-Course Tuberculosis-Preventive Therapy.Clin Infect Dis2024https://conductscience.org/library/papers/37879092PubMed
36622148High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus.Antimicrob Agents Chemother2023https://conductscience.org/library/papers/36622148PubMed
35576223Incidence of tuberculosis among PLHIV on antiretroviral therapy who initiated isoniazid preventive therapy: A multi-center retrospective cohort study.PLoS One2022https://conductscience.org/library/papers/35576223PubMed
35086616The need for effective drugs for TB prevention: set your goals high, and don´t stop till you get there.Int J Tuberc Lung Dis2022https://conductscience.org/library/papers/35086616PubMed
34407070
"If I've got latent TB, I would like to get rid of it": Derivation of the CARD (Constraints, Actions, Risks, and Desires) Framework informed by South African healthcare worker perspectives on latent tuberculosis treatment.
PLoS One2021https://conductscience.org/library/papers/34407070PubMed
32564076A Randomized Controlled Trial of Isoniazid to Prevent Mycobacterium tuberculosis Infection in Kenyan Human Immunodeficiency Virus-Exposed Uninfected Infants.Clin Infect Dis2021https://conductscience.org/library/papers/32564076PubMed
32344637Vaccination with Alpha-Gal Protects Against Mycobacterial Infection in the Zebrafish Model of Tuberculosis.Vaccines (Basel)2020https://conductscience.org/library/papers/32344637PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/31364692

GET https://conductscience.org/api/papers/v1/31364692/references?page=2